CSIMarket
 


Exelixis Inc   (EXEL)
Other Ticker:  
 
 

EXEL's Income from Cont. Operations Growth by Quarter and Year

Exelixis Inc 's Income from Cont. Operations results by quarter and year




EXEL Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 188.56 -61.60 336.06 28.39
III Quarter September 6.86 165.25 91.46 -32.04
II Quarter June 181.56 159.18 96.09 66.82
I Quarter March 88.31 153.80 1.60 48.61
FY   465.29 416.63 525.21 111.78



EXEL Income from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Exelixis Inc in the fourth quarter 2023 achieved Income from Cont. Operations of $ 188.56 millions compare to loss from continued operations recorded in same quarter a year ago.

According to the results reported in the fourth quarter 2023, Exelixis Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Exelixis Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2023.




EXEL Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - 1083.73 % -58.7 %
III Quarter September -95.85 % 80.68 % - -
II Quarter June 14.06 % 65.66 % 43.8 % -15.46 %
I Quarter March -42.58 % 9512.5 % -96.71 % -35.85 %
FY   11.68 % -20.67 % 369.86 % -65.18 %

Financial Statements
Exelixis Inc 's fourth quarter 2023 Income from Cont. Operations $ 188.56 millions EXEL's Income Statement
Exelixis Inc 's fourth quarter 2022 Income from Cont. Operations $ -61.60 millions Quarterly EXEL's Income Statement
New: More EXEL's historic Income from Cont. Operations Growth >>


EXEL Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 2648.64 % - 267.44 % -
III Quarter September -96.22 % 3.81 % -4.82 % -
II Quarter June 105.59 % 3.5 % 5905.63 % 37.46 %
I Quarter March - -54.23 % -94.36 % -29.28 %
FY (Year on Year)   11.68 % -20.67 % 369.86 % -65.18 %




Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Exelixis Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
5902 % 386.29 % -96.22 %
(Jul 02 2021)  


EXEL's IV. Quarter Q/Q Income from Cont. Operations Comment
Exelixis Inc achieved in the IV. Quarter 2023 above company average sequential Income from Cont. Operations doubling of 2648.64%, to $ 188.56 millions, from $6.86 millions in the third quarter.
EXEL is undergoing a remarkable growth, not just recording above regular gain, and also accelerating speed, Elijah H. Wilson, market consultant mentioned.

Within Biotechnology & Pharmaceuticals industry Exelixis Inc achieved highest sequential Income from Cont. Operations growth. While Exelixis Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 5.


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #1
Overall #5
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #1
Overall #5
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
5902 % 386.29 % -96.22 %
(Jul 02 2021)  


EXEL's IV. Quarter Q/Q Income from Cont. Operations Comment
Exelixis Inc achieved in the IV. Quarter 2023 above company average sequential Income from Cont. Operations doubling of 2648.64%, to $ 188.56 millions, from $6.86 millions in the third quarter.
Exelixis Inc is undergoing a remarkable growth, with reporting higher then regular increase, but also improving speed, Elijah H. Wilson, market consultant added.

Within Biotechnology & Pharmaceuticals industry Exelixis Inc achieved highest sequential Income from Cont. Operations growth. While Exelixis Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 5.


Exelixis Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 29 2023)
12 Months Ending
(Sep 29 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 30 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ 465.29 $ 215.13 $ 373.52 $ 351.14 $ 416.63
Y / Y Income from Cont. Operations Growth (TTM) 11.68 % -73.58 % -49.56 % -48.17 % -20.67 %
Year on Year Income from Cont. Operations Growth Overall Ranking # 271 # 49 # 11 # 35 # 69
Seqeuential Income from Cont. Operations Change (TTM) 116.28 % -42.41 % 6.37 % -15.72 % -48.83 %
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 319 # 515 # 298 # 623 # 163




Cumulative Income from Cont. Operations growth Comment
Although Exelixis Inc 's Annual Income from Cont. Operations growth year on year were below company's average 252.18% , Income from Cont. Operations announced in the Dec 29 2023 period, show improvement in Income from Cont. Operations trend, to cumulative trailing twelve month growth of 11.68% year on year, from -73.58% in Sep 29 2023.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 49 to 271.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
3138.13 %
252.18 %
-77.96 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 3
Healthcare Sector # 17
Overall # 271

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
3138.13 %
252.18 %
-77.96 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 17
S&P 500 # 319
Cumulative Income from Cont. Operations growth Comment
Although Exelixis Inc 's Annual Income from Cont. Operations growth year on year were below company's average 252.18% , Income from Cont. Operations announced in the Dec 29 2023 period, show improvement in Income from Cont. Operations trend, to cumulative trailing twelve month growth of 11.68% year on year, from -73.58% in Sep 29 2023.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 49 to 271.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
3138.13 %
252.18 %
-77.96 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 3
Healthcare Sector # 17
Overall # 271

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
3138.13 %
252.18 %
-77.96 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 17
S&P 500 # 319




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
EXEL's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for EXEL's Competitors
Income from Cont. Operations Growth for Exelixis Inc 's Suppliers
Income from Cont. Operations Growth for EXEL's Customers

You may also want to know
EXEL's Annual Growth Rates EXEL's Profitability Ratios EXEL's Asset Turnover Ratio EXEL's Dividend Growth
EXEL's Roe EXEL's Valuation Ratios EXEL's Financial Strength Ratios EXEL's Dividend Payout Ratio
EXEL's Roa EXEL's Inventory Turnover Ratio EXEL's Growth Rates EXEL's Dividend Comparisons



Companies with similar Income from Cont. Operations doubling for the quarter ending Dec 29 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 29 2023
Charles River Laboratories International inc -0.08%$ -0.081 millions
Sanuwave Health Inc -0.23%$ -0.232 millions
Regeneron Pharmaceuticals Inc -3.13%$ -3.133 millions
Haemonetics Corporation-5.17%$ -5.169 millions
Resmed Inc -7.16%$ -7.165 millions
Edwards Lifesciences Corporation-7.20%$ -7.204 millions
Bristol myers Squibb Company-12.99%$ -12.988 millions
Gilead Sciences Inc -13.23%$ -13.227 millions
Utah Medical Products Inc-13.50%$ -13.499 millions
Alpha Tau Medical Ltd -13.64%$ -13.640 millions
Masimo Corp-17.13%$ -17.125 millions
Merit Medical Systems Inc-17.28%$ -17.281 millions
Fresenius Medical Care Ag-18.10%$ -18.099 millions
Qiagen N v -19.35%$ -19.354 millions
Star Equity Holdings Inc -27.24%$ -27.239 millions
Mettler toledo International Inc -30.49%$ -30.485 millions
Avantor Inc -30.49%$ -30.487 millions
Sanofi-35.93%$ -35.926 millions
Icu Medical Inc-38.15%$ -38.151 millions
Amedisys Inc -39.71%$ -39.707 millions
Embecta Corp -42.90%$ -42.898 millions
Pro dex Inc -43.12%$ -43.117 millions
Becton Dickinson And Company-44.79%$ -44.794 millions
Bio techne Corp-45.08%$ -45.075 millions
Harmony Biosciences Holdings inc -45.15%$ -45.150 millions
Exagen Inc -45.72%$ -45.721 millions
Amgen Inc -52.54%$ -52.537 millions
Biogen Inc -54.70%$ -54.704 millions
Taro Pharmaceutical Industries Ltd-56.33%$ -56.330 millions
Bio rad Laboratories Inc -58.04%$ -58.043 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com